UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000032175
Receipt number R000036686
Scientific Title Prophylaxis of post-bronchoscopy pneumonia with antibiotics based on a risk prediction score
Date of disclosure of the study information 2018/04/17
Last modified on 2020/10/11 21:09:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prophylaxis of post-bronchoscopy pneumonia with antibiotics based on a risk prediction score

Acronym

PPAP study

Scientific Title

Prophylaxis of post-bronchoscopy pneumonia with antibiotics based on a risk prediction score

Scientific Title:Acronym

PPAP study

Region

Japan


Condition

Condition

pneumonia

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the prevalence of post-bronchoscopy pneumonia in high-risk cases treated with prophylactic antibiotics

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Prevalence of post-bronchoscopy pneumonia in the cases treated with prophylactic antibiotics

Key secondary outcomes

1. Proportion of unexpected changes in the treatment of lung cancer within 30 days after bronchoscopy in the cases treated with prophylactic antibiotics
2. Prevalence of post-bronchoscopy pneumonia in the cases who failed to receive the scheduled treatment with prophylactic antibiotics
3. Prevalence of adverse effects of prophylactic antibiotic treatment
4. Risk factors of post-bronchoscopy pneumonia
5. Prevalence of post-bronchoscopy pneumonia in the cases treated with prophylactic antibiotics, excluding the cases examined with endobronchial ultrasonography-guide sheath method


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Medicine

Interventions/Control_1

Sulbactam / Ampicillin 1.5g, intravenous drip infusion within 1 hour before bronchoscopy, then Augmentin Combination Tablets (Potassium Clavulanate, Amoxicillin Hydrate) 750 mg, Amoxicillin Hydrate 750mg, tid for 3 days. If eGFR is 10-49 mL/min, dose of Augmentin Combination Tablets and Amoxicillin Hydrate is reduced to 500 mg, bid.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Trans-bronchial tumor biopsy for the diagnosis of lung cancer is scheduled
2. High risk patient for post-bronchoscopy pneumonia; two or more factors among "age 70 years or older", "current smoker", "presence of central lesion on chest CT scan" are positive
3. Written informed consent has been obtained

Key exclusion criteria

1. Presence of active infection at bronchoscopy
2. Body temperature 37 degree Celcius or higher at bronchoscopy
3. History of antibiotic therapy within 2 weeks prior to bronchoscopy
4. History of drug allergy to beta-lactam antibiotics
5. Presence of severe renal dysfunction with eGFR less than 10 mL/min
6. Other reasons which researchers consider inadequate to include in the study

Target sample size

120


Research contact person

Name of lead principal investigator

1st name Koichiro
Middle name
Last name Asano

Organization

Tokai University School of Medicine

Division name

Division of Pulmonary Medicine, Department of Medicine

Zip code

2591193

Address

143 Shimokasuya, Isehara, Kanagawa, Japan

TEL

+81463931121

Email

ko-asano@tokai-u.jp


Public contact

Name of contact person

1st name Naoki
Middle name
Last name Hayama

Organization

Tokai University School of Medicine

Division name

Division of Pulmonary Medicine, Department of Medicine

Zip code

2591193

Address

143 Shimokasuya, Isehara, Kanagawa, Japan

TEL

+81463931121

Homepage URL


Email

hayama@is.icc.u-tokai.ac.jp


Sponsor or person

Institute

Tokai University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Tokai University School of Medicine

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board for Clinical Research, Tokai University

Address

143 Shimokasuya, Isehara, Kanagawa, Japan

Tel

+81463931121

Email

tokai-rinsho@ml.tokai-u.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東海大学医学部付属病院(神奈川県)


Other administrative information

Date of disclosure of the study information

2018 Year 04 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 01 Month 04 Day

Date of IRB

2017 Year 12 Month 15 Day

Anticipated trial start date

2018 Year 04 Month 17 Day

Last follow-up date

2020 Year 04 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 04 Month 10 Day

Last modified on

2020 Year 10 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036686


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name